Elicit: Resistance Mechanisms in Enzalutamide Therapy

Resistance Mechanisms in Enzalutamide Therapy

What resistance mechanisms emerge during enzalutamide therapy?

Enzalutamide resistance mechanisms include AR pathway alterations (amplifications, mutations, splice variants), bypass signaling pathways (JAK2-STAT5, glucocorticoid receptor), metabolic adaptations (AKR1C3, HMGCR), and lineage plasticity, primarily through clonal selection of pre-existing heterogeneity rather than newly acquired mutations.

Abstract

Resistance to enzalutamide in castration-resistant prostate cancer involves multiple mechanisms operating at both androgen receptor-dependent and AR-independent levels. AR pathway alterations represent the most extensively validated resistance mechanisms, with AR amplifications increasing from 53.9% at baseline to 64.7% at progression. Specific AR mutations (H875Y, F877L, T878A/S) detected in approximately 15% of patients with progressive disease, and AR-V7 splice variants rising from 29% at baseline to 40% during treatment. However, a substantial proportion of resistance mechanisms are pre-existing rather than purely acquired, with 73.1% of baseline biopsies showing AR pathway alterations and 92.3% harboring tumor suppressor mutations (PTEN, RB1, TP53), indicating that clonal selection during treatment intensifies pre-existing heterogeneity. Bypass signaling pathways emerge as alternative resistance mechanisms, including JAK2-STAT5 activation through a positive feed-forward loop induced by enzalutamide-liganded AR, glucocorticoid receptor upregulation confirmed in clinical samples, and metabolic adaptations involving AKR1C3 and HMGCR that enable intracrine androgen synthesis. The spectrum of resistance mechanisms varies by prior treatment exposure, with specific AR mutations (L702H, T878A) enriched in abiraterone-pretreated patients. Therapeutic strategies targeting these mechanisms include combination approaches with PARP inhibitors (TALAPRO-2 trial), EZH2 inhibitors (MEVPRO-2 trial), JAK2 inhibitors, and metabolic pathway inhibitors including statins and indomethacin.

Methods

We analyzed 10 sources from an initial pool of 200, using 7 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question.

Records from Elicit search

n = 200

Papers screened using: Enzalutamide Treatment, Resistance Mechanisms, Patient Population, Study Design, Acquired Resistance Focus, Enzalutamide-Specific Focus, Sample Size Adequacy

n = 200: Papers screened out
n = 190: Papers included for extraction
n = 10

Paper search

We performed a semantic search across over 138 million academic papers from the Elicit search engine. We ran the query: “What resistance mechanisms emerge during enzalutamide therapy?” The search returned 200 total results from Elicit.

Screening

We screened in sources based on their abstracts that met these criteria:

Enzalutamide Treatment: Does this study involve patients treated with enzalutamide?
Resistance Mechanisms: Does this study investigate, describe, or analyze resistance mechanisms to enzalutamide?
Patient Population: Does this study include patients with castration-resistant prostate cancer (CRPC) or metastatic castration-sensitive prostate cancer (mCSPC)?
Study Design: Is this an original research study (clinical trial, cohort study, case-control study, cross-sectional study), systematic review, meta-analysis, or laboratory study (in vitro/in vivo) with clinical relevance?
Acquired Resistance Focus: Does this study examine resistance that develops after treatment exposure (acquired resistance) rather than focusing exclusively on primary resistance without treatment exposure?
Enzalutamide-Specific Focus: Does this study focus on enzalutamide resistance specifically, rather than solely examining other antiandrogen therapies without enzalutamide comparison?
Sample Size Adequacy: If this is a case report or case series, does it include 5 or more patients? (Answer “Yes” if this is not a case report/case series)

We considered all screening questions together and made a holistic judgement about whether to screen in each paper.

Data extraction

We asked a large language model to extract each data column below from each paper.

Resistance Mechanisms: Extract all specific molecular resistance mechanisms to enzalutamide identified in this study, including:
- Specific genes, proteins, or pathways involved (e.g., AR mutations, JAK2-STAT5, AKR1C3)
- Type of alteration (amplification, mutation, overexpression, pathway activation)
- Location if relevant (e.g., specific AR mutation sites)
- Multiple mechanisms if identified in the same study
Evidence Type: Extract the type of evidence used to identify and validate each resistance mechanism, including:
- Cell line studies (specify if parental vs resistant cell lines)
- Patient tissue samples (baseline, progression, or both)
- Xenograft/animal models
- Circulating tumor cells or cell-free DNA
- Ex vivo tumor explants
- Combination of evidence types
Mechanistic Basis: Extract detailed explanation of HOW each identified mechanism contributes to enzalutamide resistance, including:
- Molecular pathway details
- Interaction with androgen receptor signaling
- Bypass mechanisms around enzalutamide’s mode of action
- Feed-forward loops or cascading effects
- Specific functional consequences that enable continued tumor growth
Clinical Validation: Extract evidence for clinical relevance of each resistance mechanism, including:
- Presence in patient samples (baseline vs progression)
- Correlation with clinical outcomes (response rates, progression-free survival)
- Frequency of occurrence in patient cohorts
- Association with prior treatments (e.g., abiraterone)
- Lack of clinical validation if only demonstrated in laboratory models
Emergence Timing: Extract information about when resistance mechanisms develop relative to enzalutamide treatment, including:
- Pre-existing (baseline) vs acquired during treatment
- Time to emergence if specified
- Clonal selection or evolution during treatment
- Comparison between baseline and progression samples
- Sequential development if multiple mechanisms identified
Therapeutic Targeting: Extract information about therapeutic strategies to overcome each resistance mechanism, including:
- Specific inhibitors or drugs tested
- Combination strategies with enzalutamide
- In vitro and in vivo efficacy data
- Clinical trials or therapeutic implications mentioned
- Theoretical targeting approaches if no specific agents tested

Results

Characteristics of Included Studies

The included studies comprise six reviews and four primary studies examining resistance mechanisms to enzalutamide in castration-resistant prostate cancer. Full text was available for six studies, while four studies were available as abstract only. The evidence types varied substantially, with most studies employing multiple complementary approaches including cell line models, patient tissue samples, circulating biomarkers, and animal models.

Resistance Mechanisms

Androgen Receptor-Dependent Mechanisms

Multiple studies identified alterations in the androgen receptor (AR) itself as central to enzalutamide resistance. These mechanisms maintain AR signaling despite enzalutamide treatment through various molecular alterations.

Mechanism	Type of Alteration	Clinical Validation	Timing of Emergence
AR amplification	Copy number gain	Detected in 53.9% at baseline, 64.7% at progression; associated with worse progression-free survival (HR 2.92)	Both pre-existing and acquired
AR mutations (H875Y, F877L, T878A/S)	Point mutations in ligand-binding domain	Observed in ~15% of progressive mCRPC patients; F877L and T878A mutations increase during treatment	Primarily acquired during treatment
AR splice variants (AR-V7)	Constitutively active truncated variants	Detected in 29% at baseline, 40% at progression; associated with shorter survival and lower PSA response rates	Both pre-existing and acquired
Heavily mutated AR (≥2 mutations)	Multiple mutations	Associated with worse progression-free survival (HR 3.94)	Acquired during treatment

AR amplification increases AR protein expression, overcoming enzalutamide’s inhibitory effects by saturating drug binding capacity. Specific point mutations in the ligand-binding domain can convert enzalutamide from an antagonist to an agonist, paradoxically promoting tumor growth. The L702H mutation exhibits glucocorticoid sensitivity, while T878A is a promiscuous mutation that emerged particularly in patients with prior abiraterone treatment. AR-V7 splice variants lack the ligand-binding domain targeted by enzalutamide, maintaining constitutive transcriptional activity and promoting target gene activation in a ligand-independent manner.

Bypass Signaling Pathways

Several studies identified alternative signaling pathways that circumvent AR inhibition, enabling tumor growth despite enzalutamide treatment.

Glucocorticoid Receptor Pathway: Glucocorticoid receptor (GR) upregulation was identified as a key bypass mechanism. GR can activate AR target genes through an alternative pathway, with dexamethasone activation sufficient to confer resistance.
JAK2-STAT5 Signaling: Enzalutamide-liganded AR induces sustained JAK2-STAT5 phosphorylation, creating a positive feed-forward loop where activated STAT5 increases JAK2 mRNA and protein levels, further activating JAK2.
PI3K/Akt/mTOR Pathway: AR inhibition increases active Akt, which activates oncogenic pathways and rescues AR protein levels.
Additional Bypass Pathways: Noncanonical Wnt signaling through Wnt5A was observed in resistant cells.

Metabolic and Steroid Biosynthesis Alterations

AKR1C3 and Cholesterol Biosynthesis: The steroid biosynthesis pathway, particularly through AKR1C3 elevation, emerged as a critical resistance mechanism. AKR1C3 converts weak androgens to more active forms, enabling intracrine androgen production that bypasses enzalutamide’s blockade of the AR.
HMGCR and Mevalonate Pathway: HMGCR, a crucial enzyme in the mevalonate pathway for cholesterol biosynthesis, is elevated in enzalutamide-resistant cells.
Other Metabolic Alterations: Metabolic changes including increased glycolysis and citric acid cycle hyperactivation provide alternative energy sources that contribute to resistance.

Tumor Suppressor Loss and Lineage Plasticity

Alteration	Frequency	Clinical Correlation	Mechanism
PTEN loss	Present in 92.3% of baseline biopsies	Associated with resistance	Affects AR signaling pathway
RB1 loss	Present in 92.3% of baseline biopsies; 13/63 baseline samples	Associated with worse progression-free survival (HR 4.46)	Drives lineage plasticity toward AR-independent neuroendocrine phenotype; affects cell cycle regulation
TP53 loss	Present in 92.3% of baseline biopsies	Associated with resistance	Combined knockdown with RB1 leads to resistance; drives lineage plasticity
BRCA2 alterations	38.5% at baseline, 64.7% at progression	Increased post-enzalutamide	May enable tumor survival despite DNA damage; involves DNA repair mechanisms

Tumor Microenvironment and Immune Mechanisms

The immunosuppressive tumor microenvironment is characterized by reduced infiltration of cytotoxic immune cells and altered cytokine expression profiles. IL6 from the tumor microenvironment activates the JAK/STAT3 pathway, promoting resistance. Immune evasion through PD-L1 upregulation was identified as a potential resistance mechanism.

Additional Molecular Mechanisms

Gene Regulatory Mechanisms: CREB5 amplification and overexpression enhances AR activity at promoters and enhancers.
Protein Homeostasis: HSP70 and AKR1C3 stabilize AR-V7 through protein homeostasis mechanisms.
MicroRNAs: Multiple microRNAs augment AR activity, including miR-346, miR-361-3p, and miR-197.

Temporal Dynamics of Resistance

The timing of resistance mechanism emergence varies substantially across different alterations. AR pathway alterations (mutations, amplifications) and tumor suppressor gene mutations (PTEN, RB1, TP53) were enriched at baseline (73.1% and 92.3% respectively). Specific AR mutations exhibit clonal selection patterns.

Therapeutic Targeting Strategies

Direct AR Targeting

Next-generation AR antagonists have been developed to overcome specific resistance mutations. Darolutamide significantly inhibits growth of enzalutamide-resistant clones both in vitro and in vivo.

Combination Strategies with Enzalutamide

DNA Repair Inhibition: The TALAPRO-2 trial evaluates talazoparib (PARP inhibitor) combined with enzalutamide.
Metabolic Pathway Inhibition: Simvastatin (HMGCR inhibitor) combined with enzalutamide significantly inhibits growth of resistant cells in vitro and tumors in vivo.

Drug Repurposing and Novel Agents

Artesunate and masofaniten (combined with enzalutamide) represent drug repurposing efforts.

Theoretical and Emerging Approaches

Targeting noncanonical Wnt signaling or Wnt5A represents a theoretical approach for Wnt pathway-driven resistance.

Synthesis

The landscape of enzalutamide resistance mechanisms reveals substantial heterogeneity across multiple molecular levels, necessitating careful interpretation of which mechanisms predominate in specific clinical contexts.